168 related articles for article (PubMed ID: 37742867)
1. The Treatment of Primary IgA Nephropathy: Change, Change, Change.
Caster DJ; Lafayette RA
Am J Kidney Dis; 2024 Feb; 83(2):229-240. PubMed ID: 37742867
[TBL] [Abstract][Full Text] [Related]
2. Novel agents for treating IgA nephropathy.
Kunter U; Seikrit C; Floege J
Curr Opin Nephrol Hypertens; 2023 Sep; 32(5):418-426. PubMed ID: 37382182
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, 'diabetic nephropathy', IgA nephropathy and podocytopathies with FSGS lesions.
Anders HJ; Peired AJ; Romagnani P
Nephrol Dial Transplant; 2022 Aug; 37(9):1609-1615. PubMed ID: 33313878
[TBL] [Abstract][Full Text] [Related]
4. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
5. IgA nephropathy in adults-treatment standard.
Gleeson PJ; O'Shaughnessy MM; Barratt J
Nephrol Dial Transplant; 2023 Oct; 38(11):2464-2473. PubMed ID: 37418237
[TBL] [Abstract][Full Text] [Related]
6. Treatment of IgA nephropathy.
Barratt J; Feehally J
Kidney Int; 2006 Jun; 69(11):1934-8. PubMed ID: 16641928
[TBL] [Abstract][Full Text] [Related]
7. Update on treatment of immunoglobulin A nephropathy.
Zhang YM; Zhang H
Nephrology (Carlton); 2018 Oct; 23 Suppl 4():62-67. PubMed ID: 30298661
[TBL] [Abstract][Full Text] [Related]
8. Current treatment of IgA nephropathy.
Floege J; Rauen T; Tang SCW
Semin Immunopathol; 2021 Oct; 43(5):717-728. PubMed ID: 34495361
[TBL] [Abstract][Full Text] [Related]
9. Treatment of IgA nephropathy: Recent advances and prospects.
Coppo R
Nephrol Ther; 2018 Apr; 14 Suppl 1():S13-S21. PubMed ID: 29606258
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
Rizk DV; Maillard N; Julian BA; Knoppova B; Green TJ; Novak J; Wyatt RJ
Front Immunol; 2019; 10():504. PubMed ID: 30941137
[TBL] [Abstract][Full Text] [Related]
11. IgA nephropathy.
Stamellou E; Seikrit C; Tang SCW; Boor P; Tesař V; Floege J; Barratt J; Kramann R
Nat Rev Dis Primers; 2023 Nov; 9(1):67. PubMed ID: 38036542
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies in immunoglobulin A nephropathy.
Yeo SC; Liew A; Barratt J
Nephrology (Carlton); 2015 Nov; 20(11):788-800. PubMed ID: 26032537
[TBL] [Abstract][Full Text] [Related]
13. IgA nephropathy: an overview of drug treatments in clinical trials.
Selvaskandan H; Gonzalez-Martin G; Barratt J; Cheung CK
Expert Opin Investig Drugs; 2022 Dec; 31(12):1321-1338. PubMed ID: 36588457
[TBL] [Abstract][Full Text] [Related]
14. Non-immunosuppressive therapies for childhood IgA nephropathy.
Shima Y; Nakanishi K; Yoshikawa N
Pediatr Nephrol; 2021 Oct; 36(10):3057-3065. PubMed ID: 33594462
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
16. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
Nagy J; Sági B; Máté J; Vas T; Kovács T
Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
[TBL] [Abstract][Full Text] [Related]
17. Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link.
Selvaskandan H; Barratt J; Cheung CK
Int J Immunogenet; 2022 Feb; 49(1):8-21. PubMed ID: 34821031
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria.
Nagasawa Y; Yamamoto R; Shinzawa M; Shoji T; Hasuike Y; Nagatoya K; Yamauchi A; Hayashi T; Kuragano T; Moriyama T; Isaka Y
Clin Exp Nephrol; 2020 Oct; 24(10):927-934. PubMed ID: 32642919
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and pathological analysis of IgA nephropathy with acute kidney injury].
Chen MG; Ye XH; Liang HY; Yang Q
Zhonghua Er Ke Za Zhi; 2016 Aug; 54(8):610-3. PubMed ID: 27510875
[TBL] [Abstract][Full Text] [Related]
20. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Wheeler DC; Toto RD; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Pecoits-Filho R; Correa-Rotter R; Rossing P; Sjöström CD; Umanath K; Langkilde AM; Heerspink HJL;
Kidney Int; 2021 Jul; 100(1):215-224. PubMed ID: 33878338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
